Ultrasensitive PCT Assay for Non-Infectious Disease Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively diagnose and predict the risk of non-infectious primary diseases in patients, as biomarkers like Procalcitonin (PCT) levels below 0.25 ng/mL may be indicative of underlying conditions that could lead to further diseases or infections, especially in patients with pre-existing primary diseases that can alter the immune system's burden.
Innovation Solution
An in vitro method involving the determination of Procalcitonin or its fragments of at least 12 amino acids in length in patient samples, correlating these levels to the risk of acquiring further diseases or conditions, particularly using an ultrasensitive assay with a lower limit of detection below 0.05 ng/mL, and combining with additional biomarkers for enhanced predictive value.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCT levels are measured using conventional assays with detection limits around 0.25 ng/mL, then sepsis diagnosis is reliable, but slightly elevated PCT levels in non-infectious diseases are undetected
Solution Approach 1:
The patent applies parameter changes by modifying the detection threshold and sensitivity parameters of the PCT assay. By using ultrasensitive assays with detection limits below 0.05 ng/mL (compared to conventional 0.25 ng/mL), the system can detect slightly elevated PCT levels in non-infectious diseases while maintaining reliability for sepsis diagnosis. This parameter change enables the detection of subtle inflammatory responses without requiring completely new assay methodologies.
2Reliability
If PCT measurement is performed in patients with non-infectious primary diseases, then risk stratification for further diseases is improved, but false positive interpretations may increase
Solution Approach 1:
The patent applies segmentation by dividing the diagnostic interpretation into distinct PCT level ranges with specific clinical meanings. It segments PCT levels into: undetectable/<0.05 ng/mL (low risk), 0.05-0.25 ng/mL (moderate risk), and >0.25 ng/mL (high risk suggestive of infection). This segmentation allows clinicians to interpret results in context, reducing false positive interpretations while maintaining improved prognosis accuracy through risk stratification.
Solution Approach 2:
The patent introduces additional biomarkers as intermediaries to support PCT interpretation. By combining PCT measurements with other inflammatory markers and clinical parameters, the system mediates the diagnostic process to distinguish between slightly elevated PCT due to non-infectious inflammation versus early infection, thereby maintaining diagnostic specificity while improving prognosis accuracy.
3Ease of operation
If conventional PCT thresholds (>0.25 ng/mL) are used, then antibiotic treatment decisions are straightforward, but patients with slightly elevated PCT levels receive inappropriate treatment
Solution Approach 1:
The patent applies dynamics by implementing dynamic treatment algorithms that adapt to different PCT level ranges. Instead of a single static threshold, the system uses dynamic decision rules: for PCT <0.05 ng/mL, no antibiotic treatment is recommended; for PCT 0.05-0.25 ng/mL, treatment decisions are guided by additional clinical parameters and biomarkers; for PCT >0.25 ng/mL, antibiotic treatment is strongly recommended. This dynamic approach maintains ease of operation through clear algorithms while improving treatment appropriateness through nuanced decision-making.
Data Source
AI summary
In vitro methods such as in vitro diagnosis, prognosis and risk stratification of a patient having a primary disease, whereby the level of Procalcitonin (PCT) or fragment thereof in a sample of a bodily fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition. Assays for performing such methods and samples containing complex resulting from such methods.